These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22551733)

  • 1. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
    Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe V; Kantarci K; Gunter JL; Senjem ML; Ivnik RJ; Roberts RO; Boeve BF; Petersen RC
    Neurology; 2012 May; 78(20):1576-82. PubMed ID: 22551733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.
    Jack CR; Knopman DS; Weigand SD; Wiste HJ; Vemuri P; Lowe V; Kantarci K; Gunter JL; Senjem ML; Ivnik RJ; Roberts RO; Rocca WA; Boeve BF; Petersen RC
    Ann Neurol; 2012 Jun; 71(6):765-75. PubMed ID: 22488240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
    Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
    JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI.
    Lowe VJ; Peller PJ; Weigand SD; Montoya Quintero C; Tosakulwong N; Vemuri P; Senjem ML; Jordan L; Jack CR; Knopman D; Petersen RC
    Neurology; 2013 Jun; 80(23):2130-7. PubMed ID: 23645596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of Alzheimer's disease using PiB and FDG PET.
    Cohen AD; Klunk WE
    Neurobiol Dis; 2014 Dec; 72 Pt A():117-22. PubMed ID: 24825318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome.
    Guo LH; Alexopoulos P; Eisele T; Wagenpfeil S; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):325-33. PubMed ID: 22932720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects.
    Squarzoni P; Faria DP; Yassuda MS; Porto FHG; Coutinho AM; Costa NAD; Nitrini R; Forlenza OV; Duran FLS; Brucki SMD; Buchpiguel CA; Busatto GF
    J Alzheimers Dis; 2020; 78(1):229-244. PubMed ID: 32986673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging beta-amyloid burden in aging and dementia.
    Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
    Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.
    Wirth M; Madison CM; Rabinovici GD; Oh H; Landau SM; Jagust WJ
    J Neurosci; 2013 Mar; 33(13):5553-63. PubMed ID: 23536070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.